Cipepofol Entered Schedule IV Without a Grace Period

Cipepofol became a Schedule IV controlled substance on August 27, 2026. The expedited statute put the rule into effect when the Drug Enforcement Administration published it.¹

The Food and Drug Administration approved Cypsedo on May 29 for induction of general anesthesia in adults undergoing surgery. Less than three months later, every organization handling the drug had to apply the federal controls for Schedule IV substances.²

Why the rule took effect at once

Congress created a special route for newly approved drugs when the Department of Health and Human Services recommends placement in Schedules II through V. The statute directs the agency to issue an interim final rule within 90 days after the later of the federal scheduling recommendation or notice of drug approval. It also makes that rule immediately effective without the normal good-cause finding.³

The agency concluded that cipepofol has an abuse potential similar to propofol and other central nervous system depressants already in Schedule IV. It also found accepted medical use in the United States and a risk of limited physical or psychological dependence relative to drugs in Schedule III.⁴

Comments and hearing requests are due September 28 under Docket No. DEA 1713. The current requirements remain in force while the agency considers them.⁵

The compliance work is role-specific

Duties depend on each handler’s role. Hospitals, pharmacies, wholesalers, manufacturers, prescribers, and anesthesia teams touch different parts of the control system, so each organization must identify the requirements attached to its work.⁶

The immediate review should cover:

• Registration. A person who manufactures, distributes, dispenses, imports, exports, conducts research with, or possesses the drug must hold the registration required for that activity unless an exemption applies.⁶
• Inventory. A registrant beginning to handle the drug must take an initial inventory on that date and include it in later biennial inventories.⁷
• Records. Purchases, receipts, distributions, administrations, and other covered transactions must enter the records required by Part 1304.⁸
• Security. Storage and access controls must satisfy the rules for Schedule III through V substances.⁹
• Labeling and prescribing. Commercial containers must bear the required schedule designation, and prescriptions must comply with the federal rules governing Schedule IV drugs.¹⁰

Where implementation can fail

In my assessment, immediate scheduling first exposes data-classification failures. A new item may already exist in the wholesaler catalog, formulary, anesthesia record, purchasing system, charge master, cabinet profile, or drug file under a noncontrolled classification. If those systems disagree, a physical count alone will not produce a reliable controlled-substance record.

Leadership should test the full path of the drug:

• Identify every location that ordered, received, stored, transferred, administered, wasted, or returned it on or after August 27.
• Confirm that each location and activity is covered by the correct registration.
• Document the initial inventory and reconcile it to purchase, administration, waste, and return records.
• Update item files, automated dispensing cabinets, anesthesia workflows, order sets, labels, and diversion-monitoring rules.
• Limit access under the applicable security standard and verify that exception reports include the new item.
• Train the people who receive, store, prescribe, administer, waste, reconcile, and investigate discrepancies.

Federal controls applied on August 27. The September deadline governs comments and hearing requests to the agency.¹¹

Review other health-law analyses, see areas of experience, or read the author’s background.